<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00447811</url>
  </required_header>
  <id_info>
    <org_study_id>3200A3-1109</org_study_id>
    <nct_id>NCT00447811</nct_id>
  </id_info>
  <brief_title>Study Evaluating MOA-728 in Subjects on Stable Methadone Maintenance</brief_title>
  <official_title>Two Ascending Single Doses Crossover, Placebo Controlled Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MOA-728 Administered Orally to Subjects on Stable Methadone Maintenance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bausch Health Americas, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bausch Health Americas, Inc.</source>
  <brief_summary>
    <textblock>
      This is a study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics
      of MOA-728 in subjects on stable methadone maintenance.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety, tolerability, and pharmacodynamics</measure>
  </secondary_outcome>
  <condition>Methadone-maintenance Subjects</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MOA-728</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of methadone treatment for at least 1 month before day -1 at a dose of â‰¥ 30
             mg/day, and a positive drug test result for methadone.

          -  Healthy as determined by the investigator on the basis of screening evaluations.

        Exclusion Criteria:

          -  Allergy to opioids (eg, codeine, morphine, or oxymorphone) or opioid antagonists (eg,
             naloxone or naltrexone).

          -  Any significant cardiovascular, hepatic, renal, respiratory, gastrointestinal,
             endocrine, immunologic, dermatologic, hematologic, neurologic, or psychiatric disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeff Cohn</last_name>
    <role>Study Director</role>
    <affiliation>Bausch Health Americas, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Willingboro</city>
        <state>New Jersey</state>
        <zip>08046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>March 13, 2007</study_first_submitted>
  <study_first_submitted_qc>March 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2007</study_first_posted>
  <last_update_submitted>November 21, 2019</last_update_submitted>
  <last_update_submitted_qc>November 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2019</last_update_posted>
  <responsible_party>
    <name_title>Jeff Cohn</name_title>
    <organization>Salix Pharmaceuticals</organization>
  </responsible_party>
  <keyword>Methadone</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

